Senseonics (NYSE:SENS) announced today that it received FDA clearance for its next-generation Eversense 365 CGM system.

Eversense 365 cleared in the U.S. as an integrated continuous glucose monitoring (iCGM) system for people with diabetes With a single sensor, the Eversense 365 system provides one year of use ...

He is a member of a number of advisory boards for companies developing novel diagnostic and therapeutic options for diabetes therapy, including Roche Diagnostics, Sanofi, Abbott, and Medtronic.

The US Food and Drug Administration (FDA) has cleared the Eversense 365 (Senseonics), an implanted continuous glucose monitoring (CGM ... on top of the implanted sensor. Glucose data are ...

With a single sensor, the Eversense 365 system provides one year of use, versus 10-14 days with short-term CGM’s for minimal life disruption “Managing diabetes can be stressful and it is ...

The UL24 Series combines a mass notification speaker that connects to a fire panel and ECS with a typical paging speaker to streamline installation. Related To: Quam Nichols Quam proudly announces ...

Examining the evolving dynamics between EU and FDA regulations for medical devices. The webinar will address the historical practice of obtaining a CE Mark in Europe first, contrasting it with the ...

The Eversense 365 has an implantable CGM sensor that only needs to be changed once a year. The company is expected to launch the 365 product early in the fourth quarter of 2024. Eversense 365, a new ...

Lingo is priced at $49 for one 14-day sensor, $89 for two sensors, or $249 for six sensors, matching Dexcom’s monthly price for its Stelo over-the-counter continuous glucose monitor (CGM). Abbott and ...

“The approval of Eversense 365 represents a significant leap in CGM innovation. Extending sensor longevity to a full year, coupled with seamless device connectivity and a high level of accuracy, ...